DOL Final PBM Transparency Rule Overview

The new ERISA fiduciary duty PBM transparency rule fundamentally shifts the burden of accountability onto plan sponsors by requiring them to actively monitor and evaluate pharmacy benefit manager relationships. Sponsors must now ensure that PBMs disclose all financial incentives, including rebates and fees, that could influence prescription drug pricing decisions. This mandate compels employers to scrutinize their current contracts and negotiate terms that prioritize patient cost savings over hidden financial arrangements. Failure to comply exposes sponsors to potential litigation and regulatory penalties, as courts increasingly recognize the fiduciary obligation to act solely in the interest of plan participants. The rule demands rigorous documentation and ongoing oversight, transforming PBM management from a passive administrative task into a critical compliance function.

Also worth reading: What are the ERISA PBM compliance best practices for mitigating fiduciary risk in 2026? · How does the ERISA PBM disclosure compliance checklist impact employer responsibilities under new federal regulations? · Can an AI PBM Transparency Audit Reveal Where Drug Dollars Really Go?

Plan sponsors must implement robust internal review processes to verify that PBMs adhere to the newly mandated disclosure standards. This involves requesting detailed reports on all payments received from manufacturers and analyzing how these payments affect out-of-pocket costs for employees. The rule also encourages sponsors to consider alternative contracting models that align PBM incentives with patient affordability. By proactively addressing these transparency requirements, employers can mitigate legal risks and potentially reduce healthcare spending. The evolving regulatory landscape, including state-level reforms like California SB 41, further underscores the urgency of adopting comprehensive PBM oversight strategies. Sponsors who neglect these duties risk facing class action lawsuits and significant reputational damage, making proactive engagement essential for maintaining fiduciary integrity and protecting plan participants from undisclosed financial conflicts.

ERISA Fiduciary Liability Risks Explained

The new ERISA fiduciary duty PBM transparency rule fundamentally shifts the liability landscape for plan sponsors by mandating detailed disclosure of pharmacy benefit manager compensation, formulary decisions, and rebate arrangements. Under the Department of Labor’s final rule, plan sponsors must now obtain and review comprehensive PBM contracts, including spread pricing, administrative fees, and manufacturer rebate retention practices. Failure to act prudently in reviewing these disclosures exposes sponsors to ERISA breach of fiduciary duty claims, as courts increasingly view PBM oversight as a core fiduciary function. The rule effectively transforms passive PBM engagement into an active, documented process requiring legal and actuarial review, creating a new standard of care that plaintiffs’ attorneys are already leveraging in class actions.

Plan sponsors face heightened litigation risk as the rule provides plaintiffs with a clear roadmap for alleging imprudent PBM selection and oversight. The DOL’s emphasis on transparency means that undisclosed or excessive PBM compensation—particularly spread pricing arrangements where PBMs retain the difference between what plans pay and what pharmacies are reimbursed—now constitutes a potential fiduciary breach. Additionally, the rule requires sponsors to evaluate whether PBM rebate practices align with plan interests, as retaining manufacturer rebates without passing savings to the plan may violate ERISA’s exclusive benefit rule. With the CAA 2026’s conflicting requirements and California’s SB 41 adding state-level obligations, sponsors must navigate overlapping compliance frameworks while documenting their fiduciary processes to defend against potential lawsuits.

New Federal Disclosure Requirements Summary

The new ERISA fiduciary duty PBM transparency rule is shifting more responsibility onto plan sponsors to actively oversee their pharmacy benefit managers. Under ERISA, plan sponsors already have a duty of prudence and loyalty, but the upcoming Department of Labor requirements make that duty far more concrete. Instead of relying on vague fee summaries, sponsors must now obtain detailed disclosures from PBMs about rebates, spread pricing, direct and indirect compensation, and potential conflicts of interest. For self-funded plans especially, this means accepting that hidden PBM revenue is no longer a gray area, but something they are expected to uncover and evaluate on a regular basis.

These obligations come with real legal and financial consequences. With ERISA class actions over prescription drug costs already moving forward, failing to request or review this data could leave plan sponsors exposed to claims of breaching their fiduciary duties. Many will need to renegotiate contracts, document their review process, and be prepared to justify their PBM selections. Ultimately, the rule does not just promote lower costs, but forces plan sponsors to prove they acted in the best interest of their participants by using the transparency they are now entitled to demand.

California SB 41 Compliance Impact

The new ERISA fiduciary duty PBM transparency rule fundamentally alters the landscape for plan sponsors by imposing strict requirements on PBMs to disclose pricing and cost structures. This shift forces sponsors to move beyond passive contract management and engage in oversight to ensure compliance with federal standards. Sponsors must assess the financial implications of these disclosures and evaluate how they might affect plan costs and benefits. The heightened duty of care means any failure to monitor PBM practices could expose the plan sponsor to fiduciary liability, necessitating a review of vendor agreements and obligations.

Furthermore, these rules demand a strategic overhaul of governance frameworks in the insurance sector. Plan sponsors should develop robust compliance protocols aligning with Department of Labor regulations while maintaining plan value. This involves increased scrutiny of PBM pricing models and renegotiation of service-level agreements to reflect transparency mandates. By prioritizing transparency and regulatory adherence, sponsors can mitigate risk and demonstrate fiduciary commitment, though the immediate burden requires careful resource allocation and legal consultation to navigate the evolving environment.

Litigation Trends and Plan Sponsor Warnings

The new ERISA fiduciary duty PBM transparency rule increases plan sponsors’ oversight burden by requiring clearer fee, rebate, and compensation disclosures from pharmacy benefit managers. Sponsors must review contracts, benchmark pricing, and document prudent decisions, because incomplete or opaque PBM arrangements can now create fiduciary exposure. The rule also aligns with broader CAA 2026 disclosure expectations, pushing employers to treat prescription drug benefits as an active governance matter rather than a delegated administrative task.

At the same time, recent ERISA class actions over prescription drug benefits signal that courts may scrutinize whether sponsors acted prudently and loyally. Plan sponsors should expect more questions about spread pricing, rebate retention, and network design, especially as federal and state reforms like California SB 41 add parallel compliance layers. The practical impact is defensive: stronger documentation, independent review, and vendor accountability can reduce litigation risk while helping sponsors negotiate better PBM terms and protect participant costs.

PBM Regulation Comparison

AreaNew Rule RequirementImpact on Plan Sponsors
Fiduciary oversightSponsors must prudently select and monitor PBMsGreater documentation and governance duties
Compensation transparencyDisclose direct and indirect PBM compensationBetter cost visibility and contract leverage
Rebate and fee reportingReport rebates, fees, and spread pricingStronger audit rights and savings opportunities
Participant protectionEnsure reasonable PBM arrangementsReduced litigation and fiduciary risk
The new ERISA fiduciary duty PBM transparency rule pushes plan sponsors to treat pharmacy benefit management as an actively governed fiduciary function. Sponsors must document PBM selection, monitor compensation, and verify that rebates and fees are reasonable. While compliance adds administrative work, it can improve cost control, strengthen contract negotiations, and reduce exposure to class-action claims.